title: Crohn's disease recurrence after total proctocolectomy with definitive ileostomy.
abstract: BACKGROUND
  Total proctocolectomy with definitive ileostomy is the ultimate treatment for refractory colonic Crohn's disease (CD). Aim of the study was to report the outcome of Crohn's disease patients after total proctocolectomy with definitive ileostomy.
  
  
  METHODS
  Between 1990 and 2005, 55 patients underwent total proctocolectomy with definitive ileostomy for Crohn's disease in our institution. None of them received preventive post-operative treatment. We studied clinical recurrence, need for immunosuppressants (IS), anti-TNF therapy and re-operation in this retrospective cohort.
  
  
  RESULTS
  Median follow-up was 5.4 years. Probabilities of clinical Crohn's disease recurrence were 4%, 27% and 39% at 1, 5 and 8 years, respectively. In multivariate analysis, clinical recurrence rate was significantly higher for patients with penetrating disease behaviour (RR 1.7 IC95% [1.5-19], p=0.05) and absence of perianal disease (RR=1.6, IC95% [1.4-10]; p=0.01). Clinical recurrences were located in terminal ileum in all cases and treated medically in 9 of 16 patients including IS or anti TNF agents in 7 cases. Probabilities of treatment with immunosuppressants or anti-TNF therapy were 4%, 15% and 15% at 1, 5 and 8 years, respectively. Nearly one third of the patients (29%) underwent surgery for mechanical complications (N=11) and/or CD recurrence (N=7). Probabilities of reoperation for Crohn's disease recurrence were 0%, 10% and 18% at 1, 5 and 8 years, respectively.
  
  
  CONCLUSIONS
  Recurrence after total proctocolectomy with definitive ileostomy for Crohn's disease is not uncommon, and in our series often required immunosuppressants or surgical procedure.
authors.affiliation: Service de Gastroentérologie, Hôpital Saint-Louis, Paris, France.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Amiot
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Gornet
authors.forename: Clotilde
authors.initials: C
authors.lastname: Baudry
authors.forename: Nicolas
authors.initials: N
authors.lastname: Munoz-Bongrand
authors.forename: Martine
authors.initials: M
authors.lastname: Auger
authors.forename: Marion
authors.initials: M
authors.lastname: Simon
authors.forename: Matthieu
authors.initials: M
authors.lastname: Allez
authors.forename: Pierre
authors.initials: P
authors.lastname: Cattan
authors.forename: Emile
authors.initials: E
authors.lastname: Sarfati
authors.forename: Marc
authors.initials: M
authors.lastname: Lémann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003082:Colectomy; D003424:Crohn Disease / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007081:Ileostomy; D007082:Ileum / Q000473:pathology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011336:Probability; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha